{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T01:10:45Z","timestamp":1785546645205,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Astellas Gene Therapies"},{"name":"Klinikum der Universit\u00e4t M\u00fcnchen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Pompe disease is caused by pathogenic variants in the <jats:italic>GAA<\/jats:italic> gene, resulting in lysosomal acid \u03b1-glucosidase (GAA) deficiency. The prevalence of Pompe disease is not well-defined, and estimates vary by geographic region. We evaluated the global epidemiology of Pompe disease and the potential reasons for differing prevalence estimates using published data from worldwide newborn screening (NBS) programs and population-based studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>A comprehensive literature search in PubMed was conducted in July 2023, updated in March 2024, and validated with an Embase search in June 2024. Search terms included Pompe disease, GSDII, prevalence, incidence, epidemiology, survival, mortality, and NBS. Studies were included based on robust epidemiological methods, the presence of disease definition, and publication within the past 5 years. We identified 1210 abstracts, of which 295 met recency criteria, 30 were deemed relevant, and 11 met all inclusion criteria.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Prevalence estimates and GAA enzyme activity cutoff values varied across geographic regions. In NBS studies, the birth prevalence of infantile-onset Pompe disease (IOPD) ranged from 1 in 297,387 in Japan to 1 in 62,186 in Taiwan, and late-onset Pompe disease (LOPD) ranged from 1 in 82,914 in Taiwan to 1 in 17,133 in Pennsylvania. Data from the French National Pompe Registry (N\u2009=\u2009246) showed an increase in diagnosis of LOPD from 2.6\/year before 2001 to 10.6\/year during 2001\u20132010 and 12.8\/year during 2011\u20132015. Enzyme cutoffs in dried blood spots varied from\u2009&lt;\u20093% of lymphocyte mean to 2.10\u00a0\u03bcmol\/L\/h to\u2009\u2264\u200918% of the daily median. Three studies noted higher prevalence in populations of African descent, and two noted a higher frequency of pseudodeficiency alleles in Asian populations.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>This scoping review confirmed that prevalence estimates differ for IOPD and LOPD and vary by geographic region, potentially by race and ethnicity. It highlights the need to standardize screening and diagnosis methods, genetic testing protocols, and uniform disease classification between IOPD and LOPD.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03679-3","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T13:19:48Z","timestamp":1746537588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Global variations in diagnostic methods and epidemiological estimates in Pompe disease: findings from a scoping review"],"prefix":"10.1186","volume":"20","author":[{"given":"Roberto","family":"Giugliani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faryn","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hani","family":"Kushlaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tmirah","family":"Haselkorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmar","family":"Zanoteli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Schoser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"3679_CR1","unstructured":"Reuser AJJ, Hirschhorn R, Kroos MA. Pompe Disease: Glycogen Storage Disease Type II, Acid \u03b1-Glucosidase (Acid Maltase) Deficiency. In: Beaudet AL, Vogelstein B, Kinzler KW, al e, editors. The Online Metabolic and Molecular Bases of Inherited Disease New York, NY: The McGraw-Hill Companies, Inc.; 2018."},{"issue":"9646","key":"3679_CR2","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ. Pompe\u2019s disease. Lancet. 2008;372(9646):1342\u201353.","journal-title":"Lancet"},{"issue":"1","key":"3679_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/ajmg.c.31324","volume":"160C","author":"PS Kishnani","year":"2012","unstructured":"Kishnani PS, Beckemeyer AA, Mendelsohn NJ. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management. Am J Med Genet C Semin Med Genet. 2012;160C(1):1\u20137.","journal-title":"Am J Med Genet C Semin Med Genet"},{"issue":"2","key":"3679_CR4","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1002\/ajmg.a.35662","volume":"161A","author":"D G\u00fcng\u00f6r","year":"2013","unstructured":"G\u00fcng\u00f6r D, Reuser AJ. How to describe the clinical spectrum in Pompe disease? Am J Med Genet A. 2013;161A(2):399\u2013400.","journal-title":"Am J Med Genet A"},{"issue":"(Suppl C)","key":"3679_CR5","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.1016\/S0149-2918(07)80468-1","volume":"29","author":"M Hagemans","year":"2007","unstructured":"Hagemans M, van der Beek N, Reuser A, van Doorn P, van der Ploeg A. Pompe disease: a continuum of clinical phenotypes. Clin Ther. 2007;29(Suppl C):S103\u20134.","journal-title":"Clin Ther"},{"issue":"5","key":"3679_CR6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, et al. Pompe disease diagnosis and management guideline. Genet Med. 2006;8(5):267\u201388.","journal-title":"Genet Med"},{"issue":"11","key":"3679_CR7","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/humu.23878","volume":"40","author":"AJJ Reuser","year":"2019","unstructured":"Reuser AJJ, van der Ploeg AT, Chien YH, Llerena J Jr, Abbott MA, Clemens PR, et al. GAA variants and phenotypes among 1,079 patients with Pompe disease: data from the Pompe Registry. Hum Mutat. 2019;40(11):2146\u201364.","journal-title":"Hum Mutat"},{"issue":"4","key":"3679_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3390\/ijns6040089","volume":"6","author":"C Ficicioglu","year":"2020","unstructured":"Ficicioglu C, Ahrens-Nicklas RC, Barch J, Cuddapah SR, DiBoscio BS, DiPerna JC, et al. Newborn screening for Pompe disease: Pennsylvania experience. Int J Neonatal Screen. 2020;6(4):89.","journal-title":"Int J Neonatal Screen"},{"issue":"2\u20133","key":"3679_CR9","first-page":"91","volume":"2","author":"MG Ausems","year":"1999","unstructured":"Ausems MG, ten Berg K, Kroos MA, van Diggelen OP, Wevers RA, Poorthuis BJ, et al. Glycogen storage disease type II: birth prevalence agrees with predicted genotype frequency. Commun Genet. 1999;2(2\u20133):91\u20136.","journal-title":"Commun Genet"},{"issue":"1","key":"3679_CR10","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ijns6010004","volume":"6","author":"BK Burton","year":"2020","unstructured":"Burton BK, Charrow J, Hoganson GE, Fleischer J, Grange DK, Braddock SR, et al. Newborn screening for pompe disease in Illinois: experience with 684,290 infants. Int J Neonatal Screen. 2020;6(1):4.","journal-title":"Int J Neonatal Screen"},{"key":"3679_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/(SICI)1096-8628(19980827)79:1<69::AID-AJMG16>3.0.CO;2-K","volume":"79","author":"F Martiniuk","year":"1998","unstructured":"Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, et al. Carrier frequency for glycogen storage diseasetype II in New York and estimates of affected individuals born with the disease. Am J Med Genet. 1998;79:69\u201372.","journal-title":"Am J Med Genet"},{"issue":"6","key":"3679_CR12","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","volume":"41","author":"C Semplicini","year":"2018","unstructured":"Semplicini C, Letard P, De Antonio M, Taouagh N, Perniconi B, Bouhour F, et al. Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study. J Inherit Metab Dis. 2018;41(6):937\u201346.","journal-title":"J Inherit Metab Dis"},{"key":"3679_CR13","doi-asserted-by":"publisher","first-page":"1221140","DOI":"10.3389\/fped.2023.1221140","volume":"11","author":"R Colburn","year":"2024","unstructured":"Colburn R, Lapidus D. An analysis of Pompe newborn screening data: a new prevalence at birth, insight and discussion. Front Pediatr. 2024;11:1221140.","journal-title":"Front Pediatr"},{"issue":"7","key":"3679_CR14","doi-asserted-by":"publisher","first-page":"467","DOI":"10.7326\/M18-0850","volume":"169","author":"AC Tricco","year":"2018","unstructured":"Tricco AC, Lillie E, Zarin W, O\u2019Brien KK, Colquhoun H, Levac D, et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann Intern Med. 2018;169(7):467\u201373.","journal-title":"Ann Intern Med"},{"issue":"1","key":"3679_CR15","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1186\/s13023-021-02146-z","volume":"16","author":"T Sawada","year":"2021","unstructured":"Sawada T, Kido J, Sugawara K, Momosaki K, Yoshida S, Kojima-Ishii K, et al. Current status of newborn screening for Pompe disease in Japan. Orphanet J Rare Dis. 2021;16(1):516.","journal-title":"Orphanet J Rare Dis"},{"key":"3679_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jpeds.2021.12.072","volume":"244","author":"NC Lee","year":"2022","unstructured":"Lee NC, Chang KL, In\u2019t Groen SLM, de Faria DOS, Huang HJ, Pijnappel W, et al. Outcome of later-onset Pompe disease identified through newborn screening. J Pediatr. 2022;244:139\u2013472.","journal-title":"J Pediatr"},{"issue":"1","key":"3679_CR17","first-page":"60","volume":"59","author":"RP Limgala","year":"2021","unstructured":"Limgala RP, Furtak V, Ivanova MM, Changsila E, Wilks F, Fidelia-Lambert MN, et al. Selective screening for lysosomal storage disorders in a large cohort of minorities of African descent shows high prevalence rates and novel variants. JIMD Rep. 2021;59(1):60\u20138.","journal-title":"JIMD Rep"},{"issue":"1","key":"3679_CR18","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ymgme.2017.03.001","volume":"121","author":"JI Navarrete-Martinez","year":"2017","unstructured":"Navarrete-Martinez JI, Limon-Rojas AE, Gaytan-Garcia MJ, Reyna-Figueroa J, Wakida-Kusunoki G, Delgado-Calvillo MDR, et al. Newborn screening for six lysosomal storage disorders in a cohort of Mexican patients: three-year findings from a screening program in a closed Mexican health system. Mol Genet Metab. 2017;121(1):16\u201321.","journal-title":"Mol Genet Metab"},{"issue":"3\u20134","key":"3679_CR19","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1159\/000494115","volume":"52","author":"A Theadom","year":"2019","unstructured":"Theadom A, Rodrigues M, Poke G, O\u2019Grady G, Love D, Hammond-Tooke G, et al. A nationwide, population-based prevalence study of genetic muscle disorders. Neuroepidemiology. 2019;52(3\u20134):128\u201335.","journal-title":"Neuroepidemiology"},{"issue":"1","key":"3679_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/ijns6010009","volume":"6","author":"H Tang","year":"2020","unstructured":"Tang H, Feuchtbaum L, Sciortino S, Matteson J, Mathur D, Bishop T, et al. The first year experience of newborn screening for pompe disease in California. Int J Neonatal Screen. 2020;6(1):9.","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"3679_CR21","doi-asserted-by":"publisher","first-page":"e000182","DOI":"10.1136\/bmjpo-2017-000182","volume":"2","author":"N Elenga","year":"2018","unstructured":"Elenga N, Verloes A, Mrsic Y, Basurko C, Schaub R, Cuadro-Alvarez E, et al. Incidence of infantile Pompe disease in the Maroon population of French Guiana. BMJ Paediatr Open. 2018;2(1):e000182.","journal-title":"BMJ Paediatr Open"},{"key":"3679_CR22","unstructured":"MYOZYME (alglucosidase alfa) Injectable for intravenous infusion. [Prescribing Information]. Cambridge, MA: Genzyme Corporation. Revised May 2014.  Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/125141s223lbl.pdf"},{"key":"3679_CR23","unstructured":"LUMIZYME (alglucosidase alfa) for injection, for intravenous use. [Prescribing Information]. Cambridge, MA: Genzyme Corporation. Revised August 2014.  Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/125291s160lbl.pdf"},{"issue":"3","key":"3679_CR24","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ymgme.2012.04.013","volume":"106","author":"SC Chiang","year":"2012","unstructured":"Chiang SC, Hwu WL, Lee NC, Hsu LW, Chien YH. Algorithm for Pompe disease newborn screening: results from the Taiwan screening program. Mol Genet Metab. 2012;106(3):281\u20136.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3679_CR25","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/ijns6010002","volume":"6","author":"PL Hall","year":"2020","unstructured":"Hall PL, Sanchez R, Hagar AF, Jerris SC, Wittenauer A, Wilcox WR. Two-tiered newborn screening with post-analytical tools for pompe disease and mucopolysaccharidosis type I results in performance improvement and future direction. Int J Neonatal Screen. 2020;6(1):2.","journal-title":"Int J Neonatal Screen"},{"issue":"1","key":"3679_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.3390\/ijns6010011","volume":"6","author":"TL Klug","year":"2020","unstructured":"Klug TL, Swartz LB, Washburn J, Brannen C, Kiesling JL. Lessons learned from pompe disease newborn screening and follow-up. Int J Neonatal Screen. 2020;6(1):11.","journal-title":"Int J Neonatal Screen"},{"issue":"51","key":"3679_CR27","doi-asserted-by":"publisher","first-page":"e9186","DOI":"10.1097\/MD.0000000000009186","volume":"96","author":"M Martinez","year":"2017","unstructured":"Martinez M, Romero MG, Guereta LG, Cabrera M, Regojo RM, Albajara L, et al. Infantile-onset Pompe disease with neonatal debut: a case report and literature review. Medicine (Baltimore). 2017;96(51):e9186.","journal-title":"Medicine (Baltimore)"},{"issue":"9813","key":"3679_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, et al. Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet. 2012;379(9813):335\u201341.","journal-title":"Lancet"},{"issue":"3","key":"3679_CR29","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. JAMA. 1999;281(3):249\u201354.","journal-title":"JAMA"},{"issue":"8","key":"3679_CR30","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/gim.2017.194","volume":"20","author":"MM Minter Baerg","year":"2018","unstructured":"Minter Baerg MM, Stoway SD, Hart J, Mott L, Peck DS, Nett SL, et al. Precision newborn screening for lysosomal disorders. Genet Med. 2018;20(8):847\u201354.","journal-title":"Genet Med"},{"key":"3679_CR31","first-page":"100734","volume":"27","author":"KS Park","year":"2021","unstructured":"Park KS. Carrier frequency and predicted genetic prevalence of Pompe disease based on a general population database. Mol Genet Metab Rep. 2021;27:100734.","journal-title":"Mol Genet Metab Rep"},{"issue":"1\u20132","key":"3679_CR32","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s004399900075","volume":"105","author":"BJ Poorthuis","year":"1999","unstructured":"Poorthuis BJ, Wevers RA, Kleijer WJ, Groener JE, de Jong JG, van Weely S, et al. The frequency of lysosomal storage diseases in The Netherlands. Hum Genet. 1999;105(1\u20132):151\u20136.","journal-title":"Hum Genet"},{"issue":"3","key":"3679_CR33","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41436-018-0129-y","volume":"21","author":"MP Wasserstein","year":"2019","unstructured":"Wasserstein MP, Caggana M, Bailey SM, Desnick RJ, Edelmann L, Estrella L, et al. The New York pilot newborn screening program for lysosomal storage diseases: report of the First 65,000 Infants. Genet Med. 2019;21(3):631\u201340.","journal-title":"Genet Med"},{"key":"3679_CR34","first-page":"117","volume":"6","author":"J Wittmann","year":"2012","unstructured":"Wittmann J, Karg E, Turi S, Legnini E, Wittmann G, Giese AK, et al. Newborn screening for lysosomal storage disorders in hungary. JIMD Rep. 2012;6:117\u201325.","journal-title":"JIMD Rep"},{"issue":"3","key":"3679_CR35","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1212\/WNL.0000000000002758","volume":"87","author":"Z Lukacs","year":"2016","unstructured":"Lukacs Z, Nieves Cobos P, Wenninger S, Willis TA, Guglieri M, Roberts M, et al. Prevalence of Pompe disease in 3,076 patients with hyperCKemia and limb-girdle muscular weakness. Neurology. 2016;87(3):295\u20138.","journal-title":"Neurology"},{"issue":"1","key":"3679_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3390\/ijns10010003","volume":"10","author":"V Gragnaniello","year":"2023","unstructured":"Gragnaniello V, Cazzorla C, Gueraldi D, Puma A, Loro C, Porcu E, et al. Light and shadows in newborn screening for lysosomal storage disorders: eight years of experience in Northeast Italy. Int J Neonatal Screen. 2023;10(1):3.","journal-title":"Int J Neonatal Screen"},{"issue":"4","key":"3679_CR37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ymgme.2012.05.017","volume":"106","author":"TM Cowan","year":"2012","unstructured":"Cowan TM, Kazerouni NN, Dharajiya N, Lorey F, Roberson M, Hodgkinson C, et al. Increased incidence of profound biotinidase deficiency among Hispanic newborns in California. Mol Genet Metab. 2012;106(4):485\u20137.","journal-title":"Mol Genet Metab"},{"issue":"1","key":"3679_CR38","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.clim.2015.02.015","volume":"158","author":"A Kwan","year":"2015","unstructured":"Kwan A, Hu D, Song M, Gomes H, Brown DR, Bourque T, et al. Successful newborn screening for SCID in the Navajo Nation. Clin Immunol. 2015;158(1):29\u201334.","journal-title":"Clin Immunol"},{"key":"3679_CR39","unstructured":"Kemper AR, Ream MA, Lam KK. Health Resources and Services Administration (HRSA) Maternal and Child Health Bureau. Review of Newborn Screening Implementation for Spinal Muscular Atrophy: Final Report. Available from: https:\/\/www.hrsa.gov\/sites\/default\/files\/hrsa\/advisory-committees\/heritable-disorders\/reports-recommendations\/sma-nbs-implementation-report.pdf"},{"issue":"12","key":"3679_CR40","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3390\/children9121829","volume":"9","author":"H Kolbel","year":"2022","unstructured":"Kolbel H, Modler L, Blaschek A, Schara-Schmidt U, Vill K, Schwartz O, et al. Parental burden and quality of life in 5q-sma diagnosed by newborn screening. Children. 2022;9(12):1829.","journal-title":"Children"},{"issue":"2","key":"3679_CR41","doi-asserted-by":"publisher","first-page":"109","DOI":"10.3233\/JND-200475","volume":"7","author":"W Muller-Felber","year":"2020","unstructured":"Muller-Felber W, Vill K, Schwartz O, Glaser D, Nennstiel U, Wirth B, et al. Infants diagnosed with spinal muscular atrophy and 4 SMN2 copies through newborn screening: opportunity or burden? J Neuromuscul Dis. 2020;7(2):109\u201317.","journal-title":"J Neuromuscul Dis"},{"issue":"4","key":"3679_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.3233\/JND-190428","volume":"6","author":"K Vill","year":"2019","unstructured":"Vill K, Kolbel H, Schwartz O, Blaschek A, Olgemoller B, Harms E, et al. One year of newborn screening for SMA - results of a German pilot project. J Neuromuscul Dis. 2019;6(4):503\u201315.","journal-title":"J Neuromuscul Dis"},{"key":"3679_CR43","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpeds.2017.06.048","volume":"190","author":"BK Burton","year":"2017","unstructured":"Burton BK, Charrow J, Hoganson GE, Waggoner D, Tinkle B, Braddock SR, et al. Newborn screening for lysosomal storage disorders in Illinois: the initial 15-month experience. J Pediatr. 2017;190:130\u20135.","journal-title":"J Pediatr"},{"issue":"2","key":"3679_CR44","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10545-017-0098-3","volume":"41","author":"AB Burlina","year":"2018","unstructured":"Burlina AB, Polo G, Salviati L, Duro G, Zizzo C, Dardis A, et al. Newborn screening for lysosomal storage disorders by tandem mass spectrometry in North East Italy. J Inherit Metab Dis. 2018;41(2):209\u201319.","journal-title":"J Inherit Metab Dis"},{"key":"3679_CR45","first-page":"100929","volume":"33","author":"V Gragnaniello","year":"2022","unstructured":"Gragnaniello V, Pijnappel P, Burlina AP, In\u2019t Groen SLM, Gueraldi D, Cazzorla C, et al. Newborn screening for Pompe disease in Italy: Long-term results and future challenges. Mol Genet Metab Rep. 2022;33:100929.","journal-title":"Mol Genet Metab Rep"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03679-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03679-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03679-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T15:03:40Z","timestamp":1746543820000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03679-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3679"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03679-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No individual persons provided data for this study. The research used publicly available data from published observational studies. Individual patient consent was not required for this secondary study using previously published observational studies.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. This manuscript contains no individual person\u2019s data in any form.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Roberto Giugliani has received unrestricted research grants from Azafaros, Chiesi, Cyclo, Instituto JCR, Jo Clemente Institute, Novartis, Paradigm, PassageBio, RegenxBio, Takeda and Sanofi, and speaker\u2019s honoraria from Astellas, Chiesi, JCR, Pfizer, Takeda, Regenxbio, Sanofi and Ultragenyx. He has participated as a scientific advisor for Amicus, JCR, PTC, RegenxBio, Takeda and Ultragenyx He declares no stocks or shares. Hani Kushlaf served as a consultant on advisory boards for Alexion AstraZeneca Rare Disease, Amgen, Catalyst Pharmaceuticals, and UCB. Erica Wright has received a grant from the U.S. Health Resources and Services Administration, honoraria for teaching at Metabolic University, and support for meeting-related travel from the Association of Public Health. Edmar Zanoteli has received consulting fees and payment\/honoraria from Sanofi, and participated on data safety monitoring boards for Sanofi. Faryn Solomon and Tmirah Haselkorn are employees of Astellas Pharma Global Development. Benedikt Schoser has received unrestricted research grants from Roche Diagnostics, Marigold Foundation Canada, AMDA Foundation USA, EU Horizon ComPASs and PaLaPin, and speaker\u2019s honoraria from Amicus, Alexion, Kedrion, Sanofi. He has participated as a scientific advisor for Amicus, Alexion, Argenx, Astellas, Avidity, Pepgen, Sanofi. He declares no stocks or shares.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"216"}}